Even as the death toll from the novel coronavirus continues to climb, a viable vaccine has yet to be developed to combat the spread of COVID-19. However, at least one researcher believes he may have found a treatment for the disease.
According to French English-language newspaper The Connexion, French research professor Didier Raoult “has reported successful results from a new treatment for COVID-19, with early tests suggesting it can stop the virus from being contagious in just six days.”
Raoult found that patients he treated with a drug called hydroxychloroquine saw “a rapid and effective speeding up of their healing process, and a sharp decrease in the amount of time they remained contagious,” The Connexion reported.
The drug has historically been used to treat malaria.
Old drug, new use?
The news of Raoult’s findings was shared by Gregory Rigano, an adviser at the Stanford University School of Medicine, who tweeted Wednesday that Raoult had released his “full peer-reviewed study,” according to The Daily Wire.
Rigano later spoke with Fox News’ Tucker Carlson about the promising new development in the fight against COVID-19, The Daily Wire reported.
“A well-controlled, peer-reviewed study carried out by the most eminent infectious disease specialist in the world…out of the south of France, in which he enrolled 40 patients, again, a well-controlled peer-review study…showed a 100% cure rate against [the] coronavirus,” Rigano said of Raoult’s study Wednesday, according to the Daily Wire.
Rigano added that the study, which has been dismissed by some as fake news, “was recently accepted to the International Journal of Antimicrobial Agents by Elsevier,” adding to its credibility.
More promising research
Indeed, despite doubts from other experts, the French researcher isn’t alone in his analysis. News.com.au recently reported that researchers in Australia had reached the same conclusions.
“It’s a potentially effective treatment,” David Paterson, who serves as director of the University of Queensland Center for Clinical Research, told the outlet. “Patients would end up with no viable coronavirus in their system at all after the end of therapy,” he explained.
Paterson said what researchers “want to do at the moment is a large clinical trial across Australia, looking at 50 hospitals. And what we’re going to compare is one drug, versus another drug, versus the combination of the two drugs,” he added, according to News.com.au.
On Thursday, Reuters reported that pharmaceutical giant Bayer AG would be donating some three million tablets of Resochin, a name-brand anti-malaria drug made of chloroquine phosphate, to the government to aid in fighting the coronavirus pandemic. Hydroxychloroquine, according to Reuters, is a generic version of the drug.